difluoromethylcyclopentane | 134134-74-0

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: difluoromethylcyclopentane
• 英文别名: (Difluoromethyl)cyclopentane
• CAS: 134134-74-0
• 化学式: C₆H₁₀F₂
• 分子量: 120.142
• InChiKey: RUGHMAVBASTTPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-溴戊醛 在 三正丁基氢锡 、 三(二甲胺基)膦 作用下， 以 正戊烷 为溶剂， 反应 15.5h， 生成 difluoromethylcyclopentane
  参考文献：
  名称：

  Dolbier Jr., William R.; Rong, Xiao X.; Bartberger, Michael D., Journal of the Chemical Society. Perkin Transactions 2 (2001), 1998, # 2, p. 219 - 231

  摘要：

  DOI：

文献信息

• [EN] CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS<br/>[FR] CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZABENZO[E]AZULÈNES UTILISÉS COMME ANTAGONISTES DES V1A
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013050334A1

  公开（公告）日：2013-04-11

  The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明提供了4H,6H-5-氧杂-2,3,10b-三唑-苯并[e]吖啶衍生物，它们作为V1a受体调节剂，特别是作为V1a受体拮抗剂，它们的制造方法，含有它们的药物组合物以及它们作为药物的使用。本发明的活性化合物作为治疗剂在末梢和中央条件下对痛经、男性或女性性功能障碍、高血压、慢性心力衰竭、不适当的抗利尿激素分泌、肝硬化、肾病综合征、焦虑、抑郁障碍、强迫症、孤独症谱系障碍、精神分裂症和攻击性行为是有用的。
• Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US20140221350A1

  公开（公告）日：2014-08-07

  The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明提供了4H,6H-5-氧杂-2,3,10b-三氮杂-苯并[e]吖啶，其作为V1a受体调节剂，特别是作为V1a受体拮抗剂，其制备方法，含有它们的药物组合物以及它们作为药物的用途。本发明的活性化合物在治疗作用上在经前痛、男性或女性性功能障碍、高血压、慢性心力衰竭、抗利尿素的不当分泌、肝硬化、肾病综合征、焦虑、抑郁症、强迫性障碍、自闭症谱系障碍、精神分裂症和攻击性行为等疾病中有用。
• NONAQUEOUS SOLVENT FOR ELECTRICAL STORAGE DEVICE
  申请人：TAKEUCHI Takashi

  公开号：US20120130135A1

  公开（公告）日：2012-05-24

  Provided is a nonaqueous solvent for an electrical storage device, including a fluorine-containing, cyclic, saturated hydrocarbon represented by the following general formula (1) and having a structure obtained by introducing one or two substituents R into a cyclopentane ring: in the general formula (1), R is represented by C n X 2n+1 , n represents an integer of 1 or more, at least one of the 2n+1 X's represents F, and the other X's each represent H.

  提供了一种用于电子储存设备的非水溶剂，包括以下一般公式（1）所代表的含氟环状饱和碳氢化合物，其结构通过在环戊烷环中引入一个或两个取代基R而获得：在一般公式（1）中，R由CnX2n+1表示，n表示大于等于1的整数，2n+1个X中至少一个表示F，其他X分别表示H。
• Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them
  申请人：BOHME Thomas

  公开号：US20100204206A1

  公开（公告）日：2010-08-12

  Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them The present invention relates to di(hetero)arylcyclohexane derivatives of the formula I, in which Ar 1 , Ar 2 , R 1 and R 2 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds which inhibit ATP-sensitive potassium channels in the heart muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as arrhythmias or a decreased contractility of the heart, such as can occur, for example, in coronary heart disease, cardiac insufficiency or cardiomyopathies. In particular, they are suitable for the prevention of sudden cardiac death. The invention furthermore relates to processes and intermediates for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  本发明涉及式I的二(杂)芳基环己烷衍生物，其制备方法、其用途以及包含它们的制药组合物。其中，Ar1、Ar2、R1和R2的含义如权利要求所示。式I的化合物是有价值的药物活性化合物，可以抑制心肌中的ATP敏感性钾通道，并适用于治疗心血管系统的疾病，如心律失常或心脏收缩力下降，例如冠心病、心力衰竭或心肌病等。特别地，它们适用于预防突发性心脏死亡。本发明还涉及制备式I化合物的过程和中间体、它们的用途以及包含它们的制药组合物。
• NONAQUEOUS SOLVENT AND NONAQUEOUS ELECTROLYTIC SOLUTION FOR ELECTRICAL STORAGE DEVICE AND NONAQUEOUS ELECTRICAL STORAGE DEVICE, LITHIUM SECONDARY BATTERY AND ELECTRIC DOUBLE LAYER CAPACITOR USING THE SAME
  申请人：Hasegawa Masaki

  公开号：US20120321964A1

  公开（公告）日：2012-12-20

  A nonaqueous solvent for an electrical storage device disclosed in the present application includes fluorine-containing cyclic saturated hydrocarbon having a structure represented by the following general formula (1) in which one or two substituents R are introduced into a cyclopentane ring; and a compound having a relative dielectric constant of 25 or higher (in general formula (1), R is represented by C n X 2n+1 where n is an integer of 1 or greater, at least one of (2n+1) pieces of X's is F, and the other X's are H).

  本申请所披露的用于电储存设备的非水溶剂包括具有以下一般式（1）所表示的含氟环状饱和烃，其中在环戊烷环中引入一个或两个取代基R;以及具有相对介电常数为25或更高的化合物（在一般式（1）中，R由CnX2n+1表示，其中n是大于等于1的整数，(2n+1)个X中至少有一个是F，其余的X是H）。